43 results found.

Chronic Hepatitis C, Hepatitis C Virus, or Compensated Cirrhosis Clinical Trial using ABT-493; ABT-530; ABT-450/r/ABT-267; ABT-333; Ribavirin (RBV)

AbbVie - Recruiting 18 years to 70 years.
- A Randomized, Open-Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-493 and ABT-530 in Adult Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection.
ABT-493; ABT-530; ABT-450/r/ABT-267; ABT-333; Ribavirin (RBV)

Hepatitis Clinical Trial using MK-5172

Merck Sharp & Dohme Corp. - Recruiting 18 years to 65 years.
- A Multiple Dose Study to Evaluate Pharmacokinetics and Hepatitis C Virus RNA Dynamics Following Administration of MK-5172 in Hepatitis C Infected Patients.
MK-5172

Hepatitis C Clinical Trial

Hologic, Inc. - Recruiting 18 years or older.
- Collection of Plasma and Serum Samples From Individuals Initiating Therapy With Sofosbuvir for Chronic Hepatitis C Virus Infection for the Clinical Evaluation of the Aptima HCV Quant Dx Assay.

Hepatitis B Chronic Infection, or Pregnancy Clinical Trial using tenofovir disoproxil fumarate; placebo

Institut de Recherche pour le Developpement - Recruiting 18 years or older.
- Phase 3, Randomized Clinical Trial to Assess the Efficacy and Safety of Tenofovir in Hepatitis B Virus Infected, s and e Antigen Positive, Pregnant Women to Prevent Perinatal Transmission Despite Infant Passive-active HBV Immunization..
tenofovir disoproxil fumarate; placebo

De Novo Autoimmune Hepatitis Clinical Trial using Pediatric transplant subject with d-AIH; Pediatric transplant subject with acute rejection; Pediatric transplant subject with chronic rejection; Adult non-transplant patients with auto-immune hepatitis; Adult non-transplant subjects with chronic hepatitis C virus; Pediatric control subjects

Yale University - Recruiting 3 Months to 50 years.
- De Novo Autoimmune Hepatitis in Pediatric Liver Transplantation.
Pediatric transplant subject with d-AIH; Pediatric transplant subject with acute rejection; Pediatric transplant subject with chronic rejection; Adult non-transplant patients with auto-immune hepatitis; Adult non-transplant subjects with chronic hepatitis C virus; Pediatric control subjects

Hepatitis C Clinical Trial using MK-5172; MK-8742; Placebo; Ribavirin

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen MK-5172 and MK-8742 ñ Ribavirin (RBV) in Subjects With Chronic Hepatitis C Virus Infection.
MK-5172; MK-8742; Placebo; Ribavirin

Hepatitis C Clinical Trial using BZF961; Ritonavir; Placebo

Novartis - Recruiting N/A or older.
- Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Determine the Safety and Antiviral Effect of 3 Days of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus (HCV) Infected Patients.
BZF961; Ritonavir; Placebo

Hepatitis C, or Human Immunodeficiency Virus Clinical Trial using Boceprevir

Erasmus Medical Center - Recruiting 18 years or older.
- Efficacy of 12 Week Boceprevir in Addition to Standard of Care Therapy Consisting of Peginterferon-alpha-2b and Ribavirin for the Treatment of Acute HCV Genotype 1 in HIV Co-infected Patients. A Proof of Concept Feasibility Clinical Trial..
Boceprevir

Hepatitis C Clinical Trial using TMC435

Janssen R&D Ireland - Recruiting 18 years or older.
- A Phase III, Open-Label, Single Arm, Rollover Trial of TMC435 in Combination With Peginterferon Alpha-2A and Ribavirin for HCV Genotype-1 Infected Subjects Who Participated in the Placebo Group of a Phase II/III TMC435 Study, or Who Received DAA Treatment in a Tibotec-Sponsored Phase I Study..
TMC435

Hepatocellular Carcinoma Clinical Trial using MASCT:Multiple Antigens Specific Cellular Therapy; The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment

SYZ Cell Therapy Co.. - Recruiting 20 years to 70 years.
- Randomized, Open-label, Multi-center Clinical Trial to Compare the Efficacy and Safety of MASCT Group' and 'Non-treatment Group' in Patient Undergone Curative Resection( RFA or Operation) for Hepatocellular Carcinoma .MASCT That Expresses Multiple Antigens Specific Cellular Therapy,Autologous Immune Cytotoxic of T-lymphocytes(CTL) Induced by Dendritic Cell(DC) Loaded With Multiple Antigens.
MASCT:Multiple Antigens Specific Cellular Therapy; The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment

Hepatitis B, Cirrhosis, or Awaiting Organ Transplant Clinical Trial using HBV vaccine

Fundaci¢n P£blica Andaluza para la gesti¢n de la Investigaci¢n en Sevilla - Recruiting 18 years to 65 years.
- Open-label, Phase III, Randomized, Clinical Trial to Evaluate the Efficacy of Two Different Hepatitis B Virus (HBV) Vaccination Schemes in Patients With Hepatic Cirrhosis Candidates to Liver Transplantation.
HBV vaccine

Hepatitis C Clinical Trial using DCV/ASV/BMS-791325

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Non-cirrhotic Subjects With Genotype 1 Chronic Hepatitis C.
DCV/ASV/BMS-791325

Hepatitis B Virus, or HIV Clinical Trial using Standard of care

University of North Carolina, Chapel Hill - Recruiting 18 years or older.
- CIDRZ-1220 Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa: a Collaborative Multi-country Prospective Cohort Analysis for International Epidemiologic Databases to Evaluate AIDS- Southern Africa (HIV/HBV-coinfection in IeDEA-SA).
Standard of care

Hepatitis C Virus Clinical Trial using 150 mg/daily chloroquine compare to placebo for 12 week; Chloroquine; placebo

Shiraz University of Medical Sciences - Recruiting 18 years to 60 years.
- .
150 mg/daily chloroquine compare to placebo for 12 week; Chloroquine; placebo

Hepatitis C, Chronic, or Human Immunodeficiency Virus Clinical Trial using DAA against HCV

Valme University Hospital - Recruiting 18 years or older.
- Security and Efficacy of Triple Therapy Including Direct-Acting Antivirals Against Chronic Hepatitis C Infection In HIV-Coinfected Patients In Real-Life Conditions: The Prospective HEPAVIR Cohort..
DAA against HCV

Hepatitis C Virus Clinical Trial using Pegylated-Interferon-lambda; Ribavirin; Daclatasvir

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 3 Study Evaluating the Safety and Efficacy of Lambda/Ribavirin/Daclatasvir in Subjects With Chronic HCV Infection and Underlying Hemophilia Who Are Treatment Na‹ve or Are Prior Relapsers to Peginterferon Alfa-2a/Ribavirin.
Pegylated-Interferon-lambda; Ribavirin; Daclatasvir

Hepatitis C Virus Clinical Trial using GS-5816

Gilead Sciences - Recruiting 18 years to 79 years.
- A Phase 1, Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Renal Function and Severe Renal Impairment.
GS-5816

Hepatitis C, Chronic Clinical Trial using peginterferon alfa-2a; ribavirin; boceprevir

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects.
peginterferon alfa-2a; ribavirin; boceprevir

Hepatitis C Clinical Trial using ABT-450/ritonavir; ABT-333; ABT-267

AbbVie - Recruiting 18 years to 80 years.
- A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection.
ABT-450/ritonavir; ABT-333; ABT-267

Pregnancy, or HBV Clinical Trial using Tenofovir DF

Hopital LariboisiŠre - Recruiting 18 years or older.
- Prevention of Hepatitis B Virus (HBV) Mother-to-Child (MTC) Transmission by Serovaccination of Newborns and Use of Tenofovir DF During the Last Trimester of Pregnancy in Mothers With HBV DNA Above 100, 000 I.U/mL.
Tenofovir DF

HBV Infection Clinical Trial

Southwest Hospital, China - Recruiting 18 years to 65 years.
- The Effect of General Anesthesia Immunosuppressive on Hepatitis B Virus Replication.

Hepatitis C Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection in a Blood Donor Population.

Hepatitis B Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Duration of Long-Term Immunity After Hepatitis B Virus Immunization.

Chronic Hepatitis B e Antigen Positive, or Chronic Hepatitis B e Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Observational Study of Persons With Hepatitis B Virus Infection in North America (Cohort Study).

Chronic Hepatitis C Virus, or Non Alcoholic Fatty Liver Disease Clinical Trial using normocaloric low cholesterol diet

University of Roma La Sapienza - Recruiting 40 years to 70 years.
- Prospective Clinical Study on the Role of the Immune Response, in Relation to Diet, in Patients With Either Chronic Hepatitis C Virus (HCV) Infection or Non Alcoholic Fatty Liver Disease (NAFLD). Director Prof. V. Barnaba, Head of Internal Medicine; Principal Investigator, Prof. C. Balsano.
normocaloric low cholesterol diet

Chronic Hepatitis C Clinical Trial using TMC647055; TMC435; Ritonavir; Ribavirin; Pegylated interferon alpha-2a (PegIFN); GSK2336805

Janssen R&D Ireland - Recruiting 18 years to 70 years.
- A Phase IIa, Open-label Trial to Evaluate the Safety, Tolerability and Efficacy of a 12 Weeks Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Chronic Genotype 1 Hepatitis C Infected Patients.
TMC647055; TMC435; Ritonavir; Ribavirin; Pegylated interferon alpha-2a (PegIFN); GSK2336805

Hepatitis B Clinical Trial

National University Hospital, Singapore - Recruiting 21 years to 45 years.
- Antigen-specific Immune Response to Hepatitis B Virus and Influenza A (H1N1 Strain) in Utero.

Hepatitis C Virus Clinical Trial using ABT-450/r/ABT-267 plus Ribavirin

AbbVie - Recruiting 18 years to 75 years.
- An Open-label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) Co-administered With Ribavirin (RBV) for 12 or 16 Weeks in Treatment-Na‹ve and Treatment-Experienced Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection With and Without Compensated Cirrhosis (GIFT-II).
ABT-450/r/ABT-267 plus Ribavirin

Human Immunodeficiency Virus (HIV), or Hepatitis C, Chronic Clinical Trial

George Washington University - Recruiting 18 years or older.
- The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System..

Hepatitis C, Chronic Clinical Trial using Telaprevir and Sofosbuvir

University of Florida - Recruiting 18 years or older.
- Open-Label Study to Evaluate the Safety and Tolerability of Telaprevir in Combination With Sofosbuvir in Treatment Naive Subjects Chronically Infected With Hepatitis C Virus Genotype 1.
Telaprevir and Sofosbuvir

Acute Hepatitis C Clinical Trial using Peginterferon alfa-2a; Ribavirin

Kirby Institute - Recruiting 16 years or older.
- Treatment of Recently Acquired Hepatitis C Virus Infection.
Peginterferon alfa-2a; Ribavirin

Chronic HIV Infection, or HCV Coinfection Clinical Trial using Fosamprenavir

Fundacion SEIMC-GESIDA - Recruiting 18 years or older.
- Randomized, Controlled, Open Label, Pilot Study to Evaluate Fosamprenavir Activity on Genotype 1 Hepatitis C Virus (HCV) Infection Evolution in Human Immunodeficiency Virus (HIV) Co-infected Subjects With Antiretroviral Treatment Including Fosamprenavir.
Fosamprenavir

HIV, or Hepatitis C Clinical Trial using Intravenous Silibinin (iSIL)

University of Zurich - Recruiting 18 years or older.
- A Phase II, Multi-center, Open-label, Interventional Study to Evaluate the Safety of Intravenous Silibinin (iSIL) and Its Effect on the Hepatitis C Virus Load in Treatment-experienced HCV-HIV Co-infected Individuals With Advanced Liver Fibrosis in the Swiss HIV Cohort Study (SHCS).
Intravenous Silibinin (iSIL)

Hepatitis C, or Infection Transmission, Maternal-Fetal Clinical Trial

University of North Carolina, Chapel Hill - Recruiting N/A or older.
- The Pathogenesis of Hepatitis C Virus Vertical Transmission.

Chronic Hepatitis C Clinical Trial

Beijing 302 Hospital - Recruiting 1 year to 18 years.
- Pharmacogenomics Study on IL28B Genetic Variants for Prediction of Drug Response in Chinese Children With HCV Infection..

Hepatitis B, or Renal Failure With Tubular Necrosis Clinical Trial using plasma and urine samples, sample with ADN

University Hospital, Limoges - Recruiting 18 years or older.
- Assessment and Monitoring of Renal Proximal Tubular Tolerance of Nucleoside and Nucleotide Analogues Using Early Screening Tools in Patients Chronically Mono-infected With Hepatitis B Virus..
plasma and urine samples, sample with ADN

Hepatitis B Clinical Trial using Entecavir prophylaxis; Therapeutic entecavir

Peking University - Recruiting 18 years or older.
- Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma.
Entecavir prophylaxis; Therapeutic entecavir

Hepatitis C Clinical Trial using rimantadine

The Leeds Teaching Hospitals NHS Trust - Recruiting 18 years to 65 years.
- A Clinical Study to Evaluate the Biological Effects of Administering Rimantadine in Patients With Hepatitis C Virus (HCV) Infection Alongside Standard Combination Therapy With Pegylated Interferon and Ribavirin.
rimantadine

Chronic Hepatitis C Clinical Trial using ChronVac-C + SOC; SOC

ChronTech Pharma AB - Recruiting 18 years to 65 years.
- A Phase II Open-Label, Randomized, Parallel Group, Safety, Tolerability and Efficacy Study of i.m. Administered CHRONVAC-C in Combination With Electroporation Followed by Standard of Care in Chronic Hepatitis C Virus Genotype 1 Infected and Treatment Na‹ve Subjects.
ChronVac-C + SOC; SOC

Liver Cirrhosis Clinical Trial

National Taiwan University Hospital - Recruiting 50 years to 70 years.
- Functional Genomics and Proteomics Towards and Understanding of Cell Signaling and Diseases--- Genomic and Proteomic Analyses of Liver Cells During Hepatitis Virus Infections and Cell Therapy (4/4).

Chronic HCV Infection, or Nonalcoholic Steatohepatitis Clinical Trial using pegylated interferon; Ribavarin

Charles University, Czech Republic - Recruiting 18 years to 60 years.
- Role of Heme Oxygenase in the Pathogenesis od Hepatocellular Injury in Chronic HCV Infection.
pegylated interferon; Ribavarin